Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Astex Therapeutics to present drug candidate data

Astex Therapeutics to present drug candidate data

29th November 2007

Astex Therapeutics has announced that data on three of its drug candidates will be presented at the American Society of Haematology’s annual meeting and exposition next month.

For four days those in attendance at Georgia’s World Congress Centre will find out about AT9283, AT7519 and AT9311.

AT9283, currently being investigated in three multi-centre clinical trials, is an inhibitor of kinases believed to play an important role in the development or progression of a variety of cancers.

Also featuring in two current multi-centre phase-one clinical trials is AT7519, a selective inhibitor of certain Cyclin-dependent kinases (Cdks).

While the third candidate, AT9311 (also known as NVP-LCQ195), is also an inhibitor of Cdks, it has a markedly different pharmacological profile than AT7519.

Harren Jhoti, chief scientific officer and executive vice-president of Astex, explained that the firm discovered all the compounds using Pyramid, its proprietary fragment-based drug discovery platform.

"Astex has discovered and is developing a number of products that may have promise in the treatment of a wide range of life-threatening haematological diseases," stated Mr Jhoti.

He added that AT9283 has already shown "early signs of clinical efficacy" as a single agent in the treatment of advanced refractory AML and CML.ADNFCR-1050-ID-18374484-ADNFCR

We currently have 9 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.